Pfizer and Allergan are set to merge in the biggest combination of the year, valued at $160 billion. It is big in terms of the total corporate assets that are being re-assigned to new owners. But is it also big in terms of the joint value that will likely be created?
The Pfizer-Allergan Deal Shouldn’t Be Just About Tax Inversion
There’s room to create joint value too.
November 24, 2015